Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges

References

• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166−178.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2403−2406.
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer. 1997;80:1717−1726.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030−2042.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187−3205.
   PubMed Web of Science ®Google Scholar
• Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002/01 multicenter, prospective trial for treatment of children with acute myeloid leukaemia. Blood. 2013;122:170−178.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453−474.
   PubMed Web of Science ®Google Scholar
• Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010;28:1766−1771.
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64–70.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A. Brenner H: improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408−1411.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71:123−131.
   PubMed Web of Science ®Google Scholar
• Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol. 1988;6:1014−1030.
   PubMed Web of Science ®Google Scholar
• Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863−871.
   PubMed Web of Science ®Google Scholar
• Bradstock KF, Janossy G, Tidman N, et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res. 1981;5:301−309.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia- current status and future perspectives. Lancet Oncol. 2001;2:597−607.
   PubMed Web of Science ®Google Scholar
• Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol. 2003;121:823−838.
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, Valsecchi MG, Gaipa G, et al. Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. Br J Haematol. 2011;155:45−52.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJ, Breit TM, Adriaansen HJ, et al. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia. 1992;6(Suppl 1):47–59.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Froschl G, Printz D, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18:703−708.
   PubMed Web of Science ®Google Scholar
• Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139−152.
   PubMedGoogle Scholar
• Rimsza LM, Larson RS, Winter SS, et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol. 2000;114:66−75.
   PubMed Web of Science ®Google Scholar
• McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98:2498−2507.
   PubMed Web of Science ®Google Scholar
• Hurwitz CA, Loken MR, Graham ML, et al. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood. 1988;72:299–307.
   PubMed Web of Science ®Google Scholar
• Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood. 1990;76:163–171.
   PubMed Web of Science ®Google Scholar
• Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol. 1998;16:3774–3781.
   PubMed Web of Science ®Google Scholar
• Lucio P, Parreira A, Van Den Beemd MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B- ALL. Leukemia. 1999;13:419–427.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550–554.
   PubMed Web of Science ®Google Scholar
• Farahat N, Morilla A, Owusu-Ankomah K, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol. 1998;101:158–164.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Fritsch G, Fleischer C, et al. Comparative phenotype mapping of normal vs malignant pediatric B- lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol. 1998;26:305–313.
   PubMed Web of Science ®Google Scholar
• Veltroni M, De Zen L, Sanzari MC, et al. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica. 2003;88:1245–1252.
   PubMed Web of Science ®Google Scholar
• Gaipa G, Basso G, Maglia O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19:49–56.
   PubMed Web of Science ®Google Scholar
• Wells DA, Sale GE, Shulman HM, et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol. 1998;110:84−94.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract Res Clin Haematol. 2010;23:347−358.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele GJ, Van De Loosdrecht AA, Schuurhuis GJ, et al. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol. 2011;153:421−436.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Berges L, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746−1751.
   PubMed Web of Science ®Google Scholar
• Olaru D, Campos L, Flandrin P, et al. Multiparametric analysis of normal and postchemotherapy bone marrow: implication for the detection of leukemia-associated immunophenotypes. Cytometry B Clin Cytom. 2008;74:17−24.
   PubMedGoogle Scholar
• Del Principe MI, Buccisano F, Maurillo L, et al. Minimal Residual Disease in Acute Myeloid Leukemia of Adults: determination, Prognostic Impact and Clinical Applications. Mediterr J Hematol Infect Dis. 2016;8:e2016052.
   PubMed Web of Science ®Google Scholar
• Terstappen LW, Safford M, Konemann S, et al. Flow cytometric characterization of acute myeloid leukemia Part II. Phenotypic heterogeneity at diagnosis. Leukemia.. 1992;6:70–80.
   PubMed Web of Science ®Google Scholar
• Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 1993;81:3083–3090.
   PubMed Web of Science ®Google Scholar
• Wood BL. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med. 2007;27:551–575.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275−1291.
   PubMed Web of Science ®Google Scholar
• Janossy G, Bollum FJ, Bradstock KF, et al. Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia. J Immunol. 1979;123:1525–1529.
   PubMed Web of Science ®Google Scholar
• Janossy G, Bollum FJ, Bradstock KF, et al. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood. 1980;56:430–441.
   PubMed Web of Science ®Google Scholar
• Orfao A, Ciudad J, Lopez-Berges MC, et al. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma. 1994;131:87–90.
   Google Scholar
• Bradstock KF, Kerr A, Kabral A, et al. Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: a comparison of acute myeloid leukaemia and normal bone marrow cells. Am J Hematol. 1986;23:43–50.
   PubMed Web of Science ®Google Scholar
• Adriaansen HJ, Hooijkaas H, Kappers-Klunne MC, et al. Double marker analysis for terminal deoxynucleotidyl transferase and myeloid antigens in acute nonlymphocytic leukemia patients and healthy subjects. Haematol Blood Transfus. 1990;33:41–49.
   PubMedGoogle Scholar
• Saeland S, Duvert V, Caux C, et al. Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells. Exp Hematol. 1992;20:24–33.
   PubMed Web of Science ®Google Scholar
• Uckun FM. Regulation of human B-cell ontogeny. Blood. 1990;76:1908–1923.
   PubMed Web of Science ®Google Scholar
• Hurwitz CA, Gore SD, Stone KD, et al. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells. Leukemia. 1992;6:233–239.
   PubMed Web of Science ®Google Scholar
• Smith RG, Kitchens SR. Phenotypic heterogeneity of TDT+ cells in the blood and bone marrow: implications for surveillance of residual leukemia. Blood. 1989;74:312–319.
   PubMed Web of Science ®Google Scholar
• Saeland S, Duvert V, Pandrau D, et al. Interleukin-7 induces the proliferation of normal human B-cell precursors. Blood. 1991;78:2229–2238.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Fritsch G, Fleischer C, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia. 1997;11:1266–1273.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Fritsch G, Fröschl G, et al. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood. 1998;92:3203–3209.
   PubMed Web of Science ®Google Scholar
• Syrjälä M, Antilla VJ, Ruutu T, et al. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens. Leukemia. 1994;8:1564–1570.
   PubMed Web of Science ®Google Scholar
• Ciudad J, Orfao A, Vidriales B, et al. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection. Haematologica. 1998;83:1069–1075.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Fritsch G, Fleischer C, et al. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. Br J Haematol. 1999;105:690–695.
   PubMed Web of Science ®Google Scholar
• Lucio P, Gaipa G, Van Lochem EG. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: international Standardization and Clinical Evaluation. Leukemia. 2001;15:1185–1192.
   PubMedGoogle Scholar
• Van Lochem EG, Wiegers YM, Van Den Beemd R, et al. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia. 2000;14:688–695.
   PubMed Web of Science ®Google Scholar
• Van Wering ER, Van Der Linden-Schrever BE, Szczepanski T, et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol. 2000;110:139–146.
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104:3078–3085.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom. 2014;86:3−14.
   Web of Science ®Google Scholar
• Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104:11008–11013.
   PubMed Web of Science ®Google Scholar
• Van Rhenen A, Van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659–2666.
   PubMed Web of Science ®Google Scholar
• Van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21:1700–1707.
   PubMed Web of Science ®Google Scholar
• Jan M, Chao MP, Cha AC, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A. 2011;108:5009–5014.
   PubMed Web of Science ®Google Scholar
• Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90:47–53.
   PubMed Web of Science ®Google Scholar
• Bahia DM, Yamamoto M, Chauffaille Mde L, et al. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance. Haematologica. 2001;86:801–806.
   PubMed Web of Science ®Google Scholar
• Zelezníková T, Babusíková O. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia. Neoplasma. 2006;53:500–506.
   PubMed Web of Science ®Google Scholar
• Voskova D, Schnittger S, Schoch C, et al. Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma. 2007;48:80–88.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–446.
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017;1:2456−2466.
   PubMedGoogle Scholar
• Campana D, Pui CH. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood. 2017;129:1913–1918.
   PubMed Web of Science ®Google Scholar
• Gaipa G, Basso G, Biondi A, et al. Detection of Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia. Cytometry B Clin Cytom. 2013;84:359−369.
   PubMed Web of Science ®Google Scholar
• Gaipa G, Cazzaniga G, Valsecchi MG, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica. 2012;97:1582−1593.
   PubMed Web of Science ®Google Scholar
• Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129:347−357.
   PubMed Web of Science ®Google Scholar
• Muzzafar T, Medeiros LJ, Wang SA, et al. Aberrant underexpression of CD81 in precursor Bcell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am.J Clin Pathol. 2009;132:692–698.
   PubMed Web of Science ®Google Scholar
• DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom. 2009;76:150–155.
   PubMed Web of Science ®Google Scholar
• Rhein P, Mitlohner R, Basso G, et al. CD11b is a therapy resistance- and minimal residual diseasespecific marker in precursor B-cell acute lymphoblastic leukemia. Blood. 2010;115:3763–3771.
   PubMed Web of Science ®Google Scholar
• Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97:2115–2120.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117:6267–6276.
   PubMed Web of Science ®Google Scholar
• Ł S, Theunissen P, Sobral Da Costa E, et al. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. J Immunol Methods. 2018. pii:S0022–1759(17)30126–6. Epub ahead of print. doi:10.1016/j.jim.2018.03.005
   Google Scholar
• Tembhare PR, Ghogale S, Ghatwai N, et al. Evaluation of New Markers for Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia: CD73 and CD86 Are the Most Relevant New Markers to Increase the Efficacy of MRD Assay. Cytometry B Clin Cytom. 2018;94:100–111.
   PubMed Web of Science ®Google Scholar
• Karawajew L, Dworzak MN, Ratei R, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica. 2015;100:935−944.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Gaipa G, Ratei R, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin Cytom. 2008;74:331–340.
   PubMed Web of Science ®Google Scholar
• Irving J, Jesson J, Virgo P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica. 2009;94:870−874.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJM, Van Der Velden VHJ, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996−4009.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908−1975.
   PubMed Web of Science ®Google Scholar
• Kalina T, Flores-Montero J, Van Der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986−2010.
   PubMed Web of Science ®Google Scholar
• Costa ES, Pedreira CE, Barrena S, et al. Automated pattern-guided principal component analysis vs. expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia. 2010;24:1927−1933.
   PubMed Web of Science ®Google Scholar
• Al-Mawali A, Gillis D, Lewis I. The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia. Am J Clin Pathol. 2009;131:16−26.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, Van Der Velden V, et al. Standardization and quality control studies of real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318–2357.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29–41.
   PubMed Web of Science ®Google Scholar
• Varella-Garcia M, Hogan CJ, Odom LF, et al. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia. 2001;15:1408–1414.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Campana D. Should evaluation for minimal residual disease be routine in acute myeloid leukemia?. Curr Opin Hematol. 2013;20:86–92.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691–2696.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ1, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111:5477−5485.
   PubMed Web of Science ®Google Scholar
• Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27:5168–5174.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99:1952–1958.
   PubMed Web of Science ®Google Scholar
• Motwani J, Jesson J, Sturch E, et al. Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre. Br J Haematol. 2009;144:133–135.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126:964−971.
   PubMed Web of Science ®Google Scholar
• Pui CH, Pei D, Coustan-Smith E, et al. Clinical Utility of Sequential Minimal Residual Disease Measurements in the Context of Risk-based Therapy in Childhood Acute Lymphoblastic Leukemia: a Prospective Study. Lancet Oncol. 2015;16:465–474.
   PubMed Web of Science ®Google Scholar
• Eveillard M, Robillard N, Arnoux I, et al. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia. Hematol Oncol. 2017;35:237–243.
   PubMed Web of Science ®Google Scholar
• Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. Br J Haematol. 1999;104:695–705.
   PubMed Web of Science ®Google Scholar
• Griesinger F, Piro-Noak M, Kaib N, et al. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol. 1999;105:241–255.
   PubMed Web of Science ®Google Scholar
• Krampera M, Vitale A, Vincenzi C, et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol. 2003;120:74–79.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia The Polish Adult Leukemia Group ALL 4–2002 MRD Study. Br J Haematol. 2008;142:227−237.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, O’Brien SM, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016;172:392–400.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Jorgensen JL, et al. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017;92:279–285.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Gajjar A, Hijiha N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia. 2004;18:499–504.
   PubMedGoogle Scholar
• Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children’s Oncology Group Study. J Clin Oncol. 2008;26:3971–3978.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Jorgensen JL, et al. Differential impact of minimal residual disease negativity according to salvage status in patients with relapsed/refractory B cell acute lymphoblastic leukemia. Cancer. 2017;123:294–302.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl GV, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicenter trial. Lancet Oncol. 2010;11:543–552.
   PubMed Web of Science ®Google Scholar
• Buldini B, Rizzati F, Masetti R, et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol. 2017;177:116–126.
   PubMed Web of Science ®Google Scholar
• Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood. 2012;120:1581–1588.
   PubMed Web of Science ®Google Scholar
• Terwijn M, Van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–3897.
   PubMed Web of Science ®Google Scholar
• Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–4131.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Hourigan C, Walter RB. The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia. Curr Hematol Malig Rep. 2017;12:547–556.
   PubMed Web of Science ®Google Scholar
• Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92:4072−4079.
   PubMed Web of Science ®Google Scholar
• Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002;16:1668−1672.
   PubMed Web of Science ®Google Scholar
• Van Der Velden VH, Joosten SA, Willemse MJ, et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia. 2001;15:1485−1487.
   PubMed Web of Science ®Google Scholar
• Elorza I, Palacio C, Dapena JL, et al. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica. 2010;95:936−941.
   PubMed Web of Science ®Google Scholar
• Leung W, Campana D, Yang J, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood. 2011;118:223−230.
   PubMed Web of Science ®Google Scholar
• Venditti A, Maurillo L, Buccisano F, et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia. 2003;17:2178−2182.
   PubMed Web of Science ®Google Scholar
• Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol. 2008 Oct 20;26(30):4944−4951.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;20(9):1190−1197.
   Google Scholar
• Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30:1456−1464.
   PubMed Web of Science ®Google Scholar
• Norkin M, Katragadda L, Zou F, et al. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J. 2017;7:634.
   PubMed Web of Science ®Google Scholar
• Mo XD, Lv M, Huang XJ, et al. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. Br J Haematol. 2017;179:184−197.
   PubMed Web of Science ®Google Scholar
• Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep. 2016;11:368–384.
   PubMed Web of Science ®Google Scholar
• Ruella M, Gill S. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin Biol Ther. 2015;15:761–766.
   PubMed Web of Science ®Google Scholar
• Ruella M, Maus MV. Catch me if you can: leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016;14:357–362.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295.
   PubMed Web of Science ®Google Scholar
• Jacoby E, Nguyen SM, Fountaine TJ, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:1–10.
   Web of Science ®Google Scholar
• Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6:1–10.
   Google Scholar
• Mejstríková E, Hrusak O, Borowitz MJ, et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017 Dec;7(12):659. .
   PubMed Web of Science ®Google Scholar
• Cherian S, Miller V, McCullouch V, et al. A Novel Flow Cytometric Assay for Detection of Residual Disease in Patients with B-Lymphoblastic Leukemia/Lymphoma Post Anti-CD19 Therapy. Cytometry Part B (Clinical Cytometry). 2018;94B:112–120.
   Google Scholar
• Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009–2017.
   PubMed Web of Science ®Google Scholar
• Arroz M, Came N, Lin P, et al. Consensus guideline on Plasma Cell Myeloma Minimal Residual Disease Analysis and Reporting. Cytometry Part B. Clinical Cytometry. 2016;90B:31–39.
   Google Scholar